Use of Stingless Bee Propolis and Geopropolis against Cancer-A Literature Review of Preclinical Studies.
Francisco Assis Nascimento PereiraJosianne Rocha BarbozaCleydlenne Costa VasconcelosAlberto Jorge Oliveira LopesMaria Nilce de Sousa RibeiroPublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Cancer is one of the major maladies affecting humankind and remains one of the leading causes of death worldwide. The investigation of the biological activities of stingless bee products, especially propolis and geopropolis, has revealed promising therapeutic properties, especially in the research on new antineoplastic agents. This literature review of preclinical trials, involving biological assays of antitumor activity and identification of the chemical composition of propolis and geopropolis of stingless bee species, describes the cytotoxicity in tumor lineages (breast, lung, ovarian, liver, mouth, pharynx, larynx, colon, stomach, colorectal, cervix, kidney, prostate, melanoma, human glioblastoma, canine osteosarcoma, erythroleukemia, human chronic myelocytic leukemia, and human promyelocytic leukemia) of propolis and geopropolis of 33 species of stingless bees. The chemical composition of propolis and geopropolis was identified, indicating that these belong to the chemical classes of phenolic acids, flavonoids, coumarins, benzophenones, anthraquinones, alkaloids, terpenes, steroids, saponins, fatty acids, and carbohydrates and are possibly responsible for the cytotoxicity in tumor cells. Apoptosis was one of the main mechanisms of cytotoxicity of extracts and substances isolated from stingless bee products. Although the results found are encouraging, other preclinical studies and clinical trials are essential for the discovery of new anticancer agents.
Keyphrases
- endothelial cells
- clinical trial
- papillary thyroid
- induced pluripotent stem cells
- pluripotent stem cells
- acute myeloid leukemia
- prostate cancer
- fatty acid
- case report
- bone marrow
- high throughput
- oxidative stress
- cell therapy
- stem cells
- randomized controlled trial
- squamous cell carcinoma
- cell proliferation
- preterm birth
- open label
- skin cancer
- phase ii
- double blind
- pi k akt